Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

Topics

Hepatocellular carcinoma · Neoadjuvant immunotherapy · Pathological response · Major pathological response · Pathologic complete response · tumour regression · Hepatectomy · relapse-free survival · neoadjuvant therapy · ICI combinations · RECIST 1.1 · Radiologic response · Barcelona Clinic Liver Cancer (BCLC) staging · portal vein thrombosis · viral chronic liver disease · cross-trial patient-level analysis · pooled analysis · phase 1 and 2 clinical trials · NeoHCC consortium · surrogate endpoint · recursive partitioning · tumour regression threshold · 90% tumour regression cutoff · 70% tumour regression cutoff · Neoadjuvant immunotherapy · Performance status · LI-RADS · surgical resection specimen · non-viable tumour percentage · hazard ratio